...
首页> 外文期刊>American Journal of Cancer Research >MicroRNA-337 regulates the PI3K/AKT and Wnt/?2-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2
【24h】

MicroRNA-337 regulates the PI3K/AKT and Wnt/?2-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2

机译:MicroRNA-337调节PI3K / AKT和Wnt /β2-catenin信号通路,通过靶向高迁移率的AT-hook 2抑制肝细胞癌的进展

获取原文
           

摘要

MicroRNAs (miRNAs) serve as major regulators during the tumorigenesis and tumor development of hepatocellular carcinoma (HCC). In addition, miRNAs may serve as new promising biomarkers for the diagnosis and prognosis and as effective therapeutic targets for patients with this malignancy. Therefore, understanding the association between miRNAs and HCC may be beneficial to discover novel therapeutic approaches towards diagnosis and treatments. Results of this study showed that miRNA-337 (miR-337) was markedly downregulated in HCC tissues and cell lines. Decreased miR-337 expression was significantly associated with the TNM stage and lymph node metastasis of HCC. Ectopic expression of miR-337 prohibited the proliferation, colony formation, migration, and invasion of HCC cells. It also promoted the apoptosis in vitro and reduced the tumor growth in vivo of these cells. High-mobility group AT-hook 2 (HMGA2) was identified as a direct target gene of miR-337 in HCC through a series of experiments. HMGA2 was significantly overexpressed in HCC tissues and negatively correlated with miR-337 expression. Moreover, the functions of HMGA2 inhibition were similar to those induced by miR-337 in HCC. Restored HMGA2 expression rescued the tumor-suppressive roles of miR-337 overexpression in HCC. Furthermore, miR-337 overexpression inhibited the activation of PI3K/AKT and Wnt/β-catenin signaling pathways in HCC both in vitro and in vivo. This study demonstrated that miR-337 may play tumor-suppressing roles in HCC, at least partly, via directly targeting HMGA2 and inhibiting the PI3K/AKT and Wnt/β-catenin signaling pathways. Therefore, miR-337 may be a novel and effective target for the therapeutic treatment of patients with HCC.
机译:微小RNA(miRNA)在肝细胞癌(HCC)的肿瘤发生和肿瘤发展过程中起主要调节作用。此外,miRNA可以作为诊断和预后的新的有前途的生物标志物,并可以作为具有这种恶性肿瘤患者的有效治疗靶标。因此,了解miRNA与HCC之间的关联可能有助于发现新颖的诊断和治疗方法。这项研究的结果表明,miRNA-337(miR-337)在HCC组织和细胞系中显着下调。 miR-337表达降低与肝癌的TNM分期和淋巴结转移密切相关。 miR-337的异位表达禁止HCC细胞的增殖,集落形成,迁移和侵袭。它还促进了这些细胞的体外凋亡并降低了它们在体内的肿瘤生长。通过一系列实验,高迁移率的AT-hook 2组(HMGA2)被确定为HCC中miR-337的直接靶基因。 HMGA2在HCC组织中显着过表达,并且与miR-337表达负相关。此外,HMGA2抑制的功能类似于miR-337在HCC中诱导的功能。恢复的HMGA2表达恢复了miR-337在肝癌中过表达的肿瘤抑制作用。此外,miR-337过表达在体外和体内均抑制HCC中PI3K / AKT和Wnt /β-catenin信号通路的激活。这项研究表明,miR-337至少部分地通过直接靶向HMGA2并抑制PI3K / AKT和Wnt /β-catenin信号通路而在HCC中发挥抑癌作用。因此,miR-337可能是治疗HCC患者的新型有效靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号